Anthony E. Altig has served as a Director since January 2009. He is the Chief Financial Officer of Biotix Holdings, a manufacturer and distributor of microbiology and molecular biology consumables. From December 2004 to June 2007, Mr. Altig served as the Chief Financial Officer of Diversa Corporation (subsequently Verenium Corporation), a public company developing specialized industrial enzymes. Prior to joining Diversa, Mr. Altig served as the Chief Financial Officer of Maxim Pharmaceuticals, Inc., a public biopharmaceutical company, from 2002 to 2004. From 2000 to 2001, Mr. Altig served as the Chief Financial Officer of NBC Internet, Inc., an internet portal company, which was acquired by General Electric. Mr. Altig's additional experience includes his role as the Chief Accounting Officer at US Web Corporation, as well as his experience serving biotechnology and other technology companies during his tenure at both PricewaterhouseCoopers LLP and KPMG LLP. Mr. Altig serves as a Director and Audit Committee member for Optimer Pharmaceuticals, Inc. and is also a Director and Audit Committee Member for Ventrus Biosciences. Mr. Altig received a BBA degree from the University of Hawaii.
Tom is currently CEO and majority shareholder of Nisim International, a manufacturer of hair and skin care products distributed on a worldwide basis. Tom is also managing partner of Quarry Hill Partners a holding company for a diversified group of manufacturing companies, with products ranging from steel storage tanks, to nuclear reactor and aerospace parts.
Tom has been the principal owner and operator of several other companies including Speedy Printing Centers, Quarry Hill Foundry Supplies, Optiplas films and Eco II plastics.
Tom has served on several boards including: Synergex (member of the audit committee) - previously a TSE listed company, Brandimensions, Balmshell Inc, YPO Ontario Chapter (Chapter Chair), Canadian Franchise Association, Canadian Association of Family Enterprise, and Ducks Unlimited and Fishing Forever Foundation.
Tom has a BSc from Michigan State University in Geological Engineering.
Adrienne L. Graves, Ph.D. has been a member of the Board since April 2005 and, from 2002 to 2010 was President and Chief Executive Officer of Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. Dr. Graves is currently a strategic advisor for Santen. Dr. Graves joined Santen Inc. in 1995 as Vice President of Clinical Affairs to initiate the company's clinical development in the U.S. Prior to joining Santen Inc., Dr. Graves spent nine years with Alcon Laboratories, Inc. ("Alcon") beginning in 1986 as a Senior Scientist. She was named Associate Director of Alcon's Clinical Science Division in 1992 and then Alcon's Director of International Ophthalmology in 1993. Dr. Graves is the author of over 30 research papers and is a member of a number of professional associations, including the Association for Research in Vision and Ophthalmology, the American Academy of Ophthalmology, the American Glaucoma Society and Women in Ophthalmology. She also serves on the Boards of the American Academy of Ophthalmology Foundation, the Pan-American Association of Ophthalmology, the American Association for Cataract and Refractive Surgery, the Glaucoma Research Foundation and the Corporation Committee for the Brown University Medical School. Dr. Graves also co-founded Ophthalmic Women Leaders. She received her B.A. in Psychology with honors from Brown University, her PhD in Psychobiology from the University of Michigan and completed a postdoctoral fellowship in Visual Neuroscience at the University of Paris.
Dr. Paul Karpecki is currently the Director of Ocular Disease Research and also works in Corneal Services at Koffler Vision Group in Lexington KY since March of 2009. In 2007 he accepted a position with the Cincinnati Eye Institute in Corneal Services after five years as Director of Research for the Moyes Eye Clinic in Kansas City. Dr. Karpecki serves on or chairs numerous optometric association committees including Chair of the Refractive Surgery Advisory Committee to the AOA and on the AOA Meetings Executive Committee. He has lectured in more than 300 symposia covering four continents and was the first Optometrist to be invited to both the Delphi International Society at Wilmer-John's Hopkins, which includes the top 25 dry eye experts in the world, and the National Eye Institute's Dry Eye Committee. This was a task force established by the U.S. Department of Health and Human Services to better understand and treat dry eye disease in women. A noted educator and author, Dr. Karpecki lectures on new technology, surgical advancements and therapeutics with an emphasis on cornea and external disease. He presently serves on eight professional journal Editorial Boards. Dr. Karpecki received his Doctorate of Optometry from Indiana University and completed a Fellowship in Cornea and Refractive Surgery at Hunkeler Eye Centers in affiliation with the Pennsylvania College of Optometry in 1994.
Dr. Richard L. Lindstrom, founder and attending surgeon of Minnesota Eye Consultants and Adjunct Professor Emeritus at the University Of Minnesota Department of Ophthalmology, is a board-certified ophthalmologist and internationally recognized leader in corneal, cataract, refractive and laser surgery. He has been at the forefront of ophthalmology's revolutionary changes throughout his career, as a recognized researcher, teacher, inventor, writer, lecturer and highly acclaimed physician and surgeon.
After graduating Magna Cum Laude from the College of Liberal Arts at the University of Minnesota, Dr. Lindstrom completed his doctorate degree in medicine in 1972. He conducted research, residency and fellowship training in cornea at the University of Minnesota and affiliated hospitals and extended his anterior segment surgery fellowship training at Mary Shiels Hospital in Dallas and was a Heed Fellow in Glaucoma at University Hospital in Salt Lake City. In 1980, Dr. Lindstrom returned to the University of Minnesota, where he spent ten years on the faculty of the Department of Ophthalmology, the last two as a full professor and the Harold G. Scheie Research Chair. He continues as Adjunct Professor Emeritus, Chairman of the Vision Foundation, and Associate Director of the Minnesota Lions Eye Bank at the University of Minnesota. He entered private practice in 1989, and has led the growth and expansion of Minnesota Eye Consultants serving as managing partner for 15 years.
He is medical director of Sightpath Medical, which includes MSS and Laser Vision. He is also medical director of Refractec.
He is Chief Medical Editor of the USA and International editions of Ocular Surgery News, which reaches 82,000 Ophthalmologists worldwide.
Dr. Lindstrom is past President of the American Society of Cataract and Refractive Surgeons. He serves on the Executive Committee and is the Chair of the ASCRS Foundation. He is also past President of the International Society of Refractive Surgery, the International Intraocular Implant Club, and the International Refractive Surgery Club. He is the Global Education Liaison of the International Society of Refractive Surgery of the American Academy of Ophthalmology. He is Chairman and CEO of Lindstrom Restoration, a three-generation family business. He has endowed funds supporting the University of Minnesota, Department of Ophthalmology, the Eye Bank Association of America, and the University of Minnesota Tennis Team.
Dr Lindstrom holds over 35 patents in ophthalmology and has developed a number of solutions, intraocular lenses and instruments that are used in clinical practices globally. He serves on the Board of Directors of AcuFocus, Inc, TLC Vision, TearLab Corporation, Refractec, the Minnesota Medical Foundation, and Inner City Tennis.
A frequent lecturer throughout the world on cornea, cataract and refractive surgery, he has presented over 40 named lectures and keynote speeches before professional societies in the U.S. and abroad, most recently giving the Blumenthal Memorial lecture in Jerusalem, Israel, the Benedetto Strampelli Medal Lecture in Rome, Italy, and the Albrecht von Garefe-Vorlesung Innovator's Lecture in Nuremberg, Germany, IIIC Medal Lecture in Berlin, Germany.
Dr. Lindstrom serves on a number of journal editorial boards, including JCRS, JRS, and Ophthalmic Surgery. He is the Honorary Editor-in-Chief of the U.S./Chinese Journal of Ophthalmology. He has co-edited seven books, published over 350 peer reviewed journal articles and 60 book chapters. His professional affiliations are extensive, including Liaison of the International Society of Refractive Surgery of the American Academy of Ophthalmology.
Donald Rindell has been a member of the Board of Directors of TearLab Corporation since March 2006. He most recently served as Senior Executive Director of Business Development for Amylin Pharmaceuticals, a position he held from 2005 - 2014. Prior to joining Amylin Pharmaceuticals, Inc., Mr. Rindell had a successful consulting practice, during which time he served as Acting President of Medical Device Group, Inc., an acute care and respiratory company, Vice President of Business Development of CardioNet, Inc., a "real-time" 24/7 cardiovascular monitoring company, and Vice President of Business Development of HandyLab, Inc., a molecular diagnostics and pharmacogenomics system company. His responsibilities included corporate marketing, mergers and acquisitions activities, product planning and new strategic initiatives. Prior to his consulting practice, he served as Vice President of Corporate Development & Strategic Planning of Advanced Tissues Sciences, Inc. ("ATS"), a La Jolla, California based biotechnology company. Prior to his tenure at ATS, Mr. Rindell was the Vice President for Global Business Management of Braun/Thermoscan, a division of The Gillette Company. At Braun/Thermoscan, he played a major role in building its medical diagnostics business to achieve sales exceeding $170 million. Mr. Rindell was also employed by Hybritech, a division of Eli Lilly and Company as Executive Director of Sales and Marketing. Mr. Rindell received his B.S. degree in Economics from the College of Wooster and an MBA from Pepperdine University Graduate School of Business.
Prior to TearLab, Mr. Vamvakas co-founded TLCVision (NASDAQ/TLCV, TSX/TLC) in 1993 where he served as President and CEO until 2003.
Mr. Vamvakas as CEO, built TLC into the largest eye care service provider organization in North America with revenues of more than $300,000,000 as TLC opened or acquired more than 100 laser eye clinics, over 200 mobile laser sites, more than 250 mobile cataract locations, several ambulatory surgery centers, and through its subsidiary Vision Source Inc. developed the largest independent Optometric Franchise with more than 2,000 locations.
TLC's stock, listed on the TSX and NASDAQ since 1996, appreciated to well over $1 billion during his tenure.
Mr. Vamvakas is also the Chairman of Greybrook Capital, a private equity investment firm based out of Toronto that is focused on acquiring and operating companies in Financial Services, Technology and Healthcare. Mr. Vamvakas is also Chairman of Brandimensions Inc and serves on the Board of Jameson Bank.
Mr. Vamvakas has received many management awards from industry and his peers.
Dr. Brock Wright BSc, MD, FRCPC, MBA is currently the Associate Dean, Clinical Affairs, Faculty of Medicine, University of Manitoba. Dr. Wright has a strong record of leadership in medicine and administration in both the public and private sector. In his current role he is responsible for working with regional health authorities in the Province of Manitoba to create an Academic Health Sciences Network where clinical care, education and research are integrated.
He has served as Senior Vice-President Clinical Services, Winnipeg Regional Health Authority, Chief Medical Officer, Winnipeg Regional Health Authority, Assistant Professor, Department of Community Health Sciences, University of Manitoba, Winnipeg. Chief Operating Officer, Health Sciences Centre, Winnipeg. Vice-President, Pathology and Laboratory Division, Health Sciences Centre, Winnipeg.
Dr. Brock received his Medical Degree in 1984 and an MBA from University of Manitoba in 1992.